LIVIVO - Search results -

Search results

Result 1 - 10 of total 18

Search options

Article ; Online: Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials.

Quant, Eudocia C / Wen, Patrick Y

2010 Volume 20, Issue 3, Page(s) 425–448

Abstract: The prognosis for glioblastoma is poor despite optimal therapy with surgery, radiation, and chemotherapy. New therapies that improve survival and quality of life are needed. Research has increased our understanding of the molecular pathways important for ...

Abstract	The prognosis for glioblastoma is poor despite optimal therapy with surgery, radiation, and chemotherapy. New therapies that improve survival and quality of life are needed. Research has increased our understanding of the molecular pathways important for gliomagenesis and disease progression. Novel agents have been developed against these targets, including receptor tyrosine kinases, intracellular signaling molecules, epigenetic abnormalities, and tumor vasculature and microenvironment. This article reviews novel therapies for glioblastoma, with an emphasis on targeted agents.
MeSH term(s)	Brain Neoplasms/complications ; Brain Neoplasms/drug therapy ; Brain Neoplasms/therapy ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/trends ; Glioblastoma/complications ; Glioblastoma/drug therapy ; Glioblastoma/therapy ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Neovascularization, Pathologic/complications ; Neovascularization, Pathologic/drug therapy
Language	English
Publishing date	2010-08
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1314594-0
ISSN	1557-9867 ; 1052-5149
ISSN (online)	1557-9867
ISSN	1052-5149
DOI	10.1016/j.nic.2010.04.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 1309: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Response assessment in neuro-oncology.

Quant, Eudocia C / Wen, Patrick Y

Current oncology reports

2010 Volume 13, Issue 1, Page(s) 50–56

Abstract: Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most ... ...

Abstract	Accuracy and reproducibility in determining response to therapy and tumor progression can be difficult to achieve for nervous system tumors. Current response criteria vary depending on the pathology and have several limitations. Until recently, the most widely used criteria for gliomas were "Macdonald criteria," based on two-dimensional tumor measurements on neuroimaging studies. However, the Response Assessment in Neuro-Oncology (RANO) Working Group has published new recommendations in high-grade gliomas and is working on recommendations for other nervous system tumors. This article reviews current response criteria for high-grade glioma, low-grade glioma, brain metastasis, meningioma, and schwannoma.
MeSH term(s)	Brain Neoplasms/diagnosis ; Brain Neoplasms/pathology ; Brain Neoplasms/secondary ; Brain Neoplasms/therapy ; Diagnostic Imaging/methods ; Disease Progression ; Glioma/diagnosis ; Glioma/pathology ; Glioma/secondary ; Glioma/therapy ; Humans ; Nervous System Neoplasms/diagnosis ; Nervous System Neoplasms/pathology ; Nervous System Neoplasms/therapy ; Practice Guidelines as Topic
Language	English
Publishing date	2010-11-18
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-010-0143-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas

Priscilla K. Brastianos / Albert E. Kim / Anita Giobbie-Hurder / Eudocia Quant Lee / Nancy Wang / April F. Eichler / Ugonma Chukwueke / Deborah A. Forst / Isabel C. Arrillaga-Romany / Jorg Dietrich / Zachary Corbin / Jennifer Moliterno / Joachim Baehring / Michael White / Kevin W. Lou / Juliana Larson / Magali A. de Sauvage / Kathryn Evancic / Joana Mora /

Naema Nayyar / Jay Loeffler / Kevin Oh / Helen A. Shih / William T. Curry / Daniel P. Cahill / Fred G. Barker / Elizabeth R. Gerstner / Sandro Santagata

Nature Communications, Vol 13, Iss 1, Pp 1-

2022 Volume 7

Abstract: Abstract High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to ... ...

Abstract	Abstract High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the results of a single-arm, open-label phase 2 trial (NCT03279692) evaluating the efficacy of pembrolizumab, a PD-1 inhibitor, in a cohort of 25 evaluable patients with recurrent and progressive grade 2 and 3 meningiomas. The primary endpoint is the proportion of patients alive and progression-free at 6 months (PFS-6). Secondary endpoints include progression-free and overall survival, best intracranial response, and toxicity. Our study has met its primary endpoint and achieved a PFS-6 rate of 0.48 (90% exact CI: 0.31–0.66) and a median PFS of 7.6 months (90% CI: 3.4–12.9 months). Twenty percent of patients have experienced one (or more) grade-3 or higher treatment-related adverse events. These results suggest that pembrolizumab exerts promising efficacy on a subset of these tumors. Further studies are needed to identify the biological facets within the meningioma TME that may drive response to immune-based therapies.
Keywords	Science ; Q
Subject code	610
Language	English
Publishing date	2022-03-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Neurologic complications of cancer drug therapies.

Lee, Eudocia Quant / Arrillaga-Romany, Isabel C / Wen, Patrick Y

Continuum (Minneapolis, Minn.)

2012 Volume 18, Issue 2, Page(s) 355–365

Abstract: Purpose of review: The purpose of this article is to review neurologic complications associated with systemic anticancer therapies.: Recent findings: Although neurologic complications from traditional chemotherapies are well described, most ... ...

Abstract	Purpose of review: The purpose of this article is to review neurologic complications associated with systemic anticancer therapies. Recent findings: Although neurologic complications from traditional chemotherapies are well described, most neurologists are less familiar with complications from agents that target specific pathways or receptors. This article also reviews the most common neurologic adverse effects associated with newer targeted agents. Summary: Patients with cancer are living longer because of earlier diagnoses and remarkable improvements in treatments. Unfortunately, both traditional chemotherapies and newer targeted agents are known to cause neurologic symptoms that can impact quality of life and play a role in limiting potential treatments. Acute, subacute, and chronic syndromes may affect the central or peripheral nervous system. Since treatments for therapy-induced neurotoxicity are limited, awareness of common neurologic complications is important to prevent permanent damage.
MeSH term(s)	Aged ; Antineoplastic Agents/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/drug therapy ; Nervous System/drug effects ; Nervous System Diseases/chemically induced ; Neurotoxicity Syndromes/etiology
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2012-04
Publishing country	United States
Document type	Case Reports ; Journal Article ; Review
ISSN	1080-2371
ISSN	1080-2371
DOI	10.1212/01.CON.0000413663.42798.64
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.

Brastianos, Priscilla K / Kim, Albert E / Giobbie-Hurder, Anita / Lee, Eudocia Quant / Wang, Nancy / Eichler, April F / Chukwueke, Ugonma / Forst, Deborah A / Arrillaga-Romany, Isabel C / Dietrich, Jorg / Corbin, Zachary / Moliterno, Jennifer / Baehring, Joachim / White, Michael / Lou, Kevin W / Larson, Juliana / de Sauvage, Magali A / Evancic, Kathryn / Mora, Joana /

Nayyar, Naema / Loeffler, Jay / Oh, Kevin / Shih, Helen A / Curry, William T / Cahill, Daniel P / Barker, Fred G / Gerstner, Elizabeth R / Santagata, Sandro

Nature communications

2022 Volume 13, Issue 1, Page(s) 1325

Abstract: High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their ... ...

Abstract	High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the results of a single-arm, open-label phase 2 trial (NCT03279692) evaluating the efficacy of pembrolizumab, a PD-1 inhibitor, in a cohort of 25 evaluable patients with recurrent and progressive grade 2 and 3 meningiomas. The primary endpoint is the proportion of patients alive and progression-free at 6 months (PFS-6). Secondary endpoints include progression-free and overall survival, best intracranial response, and toxicity. Our study has met its primary endpoint and achieved a PFS-6 rate of 0.48 (90% exact CI: 0.31-0.66) and a median PFS of 7.6 months (90% CI: 3.4-12.9 months). Twenty percent of patients have experienced one (or more) grade-3 or higher treatment-related adverse events. These results suggest that pembrolizumab exerts promising efficacy on a subset of these tumors. Further studies are needed to identify the biological facets within the meningioma TME that may drive response to immune-based therapies.
MeSH term(s)	Antibodies, Monoclonal, Humanized/adverse effects ; Disease Progression ; Humans ; Meningeal Neoplasms/drug therapy ; Meningioma/drug therapy ; Tumor Microenvironment
Chemical Substances	Antibodies, Monoclonal, Humanized ; pembrolizumab (DPT0O3T46P)
Language	English
Publishing date	2022-03-14
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-022-29052-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Recurrent high-grade glioma.

Quant, Eudocia C / Drappatz, Jan / Wen, Patrick Y / Norden, Andrew D

Current treatment options in neurology

2010 Volume 12, Issue 4, Page(s) 321–333

Abstract: Opinion statement: Opinions vary on the best treatment options for recurrent high-grade glioma. Some argue that bevacizumab should become standard of care for patients with recurrent glioblastoma, especially in light of recent FDA approval for this ... ...

Abstract	Opinion statement: Opinions vary on the best treatment options for recurrent high-grade glioma. Some argue that bevacizumab should become standard of care for patients with recurrent glioblastoma, especially in light of recent FDA approval for this indication. However, this opinion is not uniformly accepted. Age, performance status, histology, tumor size and location, O6-methylguanine-DNA methyltransferase (MGMT) methylation status for glioblastoma, 1p/19q status for oligodendroglial tumors, and the number and types of prior therapies are important considerations. In addition, recurrent disease must be distinguished from "pseudoprogression" due to treatment effects. Enrollment in a clinical trial is the optimal choice for most patients with recurrent high-grade glioma after failure of radiation therapy and temozolomide. For patients who are ineligible or do not have access to clinical trials, then either bevacizumab monotherapy or bevacizumab in combination with a second agent such as irinotecan is recommended. Involved-field external beam radiation should be considered for patients with anaplastic gliomas who have not received radiation. For patients with anaplastic astrocytoma who progress after radiotherapy, temozolomide may be used. For patients with anaplastic oligodendroglioma who progress after radiotherapy, PCV chemotherapy and temozolomide are options. Oligodendroglial tumors with 1p/19q deletions are more likely to respond to treatment. In the past, carmustine was commonly used to treat recurrent high-grade glioma, but the utility of carmustine in the modern era is unknown because most studies were performed prior to the widespread use of temozolomide. High-precision re-irradiation such as stereotactic radiosurgery is another option in high-grade glioma, especially for patients with poor bone marrow reserve or inability to tolerate chemotherapy, but there is a paucity of studies with adequate controls. Surgery may be useful as adjuvant treatment for patients with symptoms due to mass effect or for patients requiring definitive histopathology, but it generally should be combined with another treatment modality. Emerging therapies, including dose-intense temozolomide regimens, targeted molecular inhibitors, other antiangiogenic therapies, viral gene therapies, immunotherapies, and convection-enhanced delivery of targeted immunotoxins, are still under investigation.
Language	English
Publishing date	2010-09-15
Publishing country	United States
Document type	Journal Article
ZDB-ID	2057342-X
ISSN	1534-3138 ; 1092-8480
ISSN (online)	1534-3138
ISSN	1092-8480
DOI	10.1007/s11940-010-0078-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5535: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Clinical trial links oncolytic immunoactivation to survival in glioblastoma.

Ling, Alexander L / Solomon, Isaac H / Landivar, Ana Montalvo / Nakashima, Hiroshi / Woods, Jared K / Santos, Andres / Masud, Nafisa / Fell, Geoffrey / Mo, Xiaokui / Yilmaz, Ayse S / Grant, James / Zhang, Abigail / Bernstock, Joshua D / Torio, Erickson / Ito, Hirotaka / Liu, Junfeng / Shono, Naoyuki / Nowicki, Michal O / Triggs, Daniel /

Halloran, Patrick / Piranlioglu, Raziye / Soni, Himanshu / Stopa, Brittany / Bi, Wenya Linda / Peruzzi, Pierpaolo / Chen, Ethan / Malinowski, Seth W / Prabhu, Michael C / Zeng, Yu / Carlisle, Anne / Rodig, Scott J / Wen, Patrick Y / Lee, Eudocia Quant / Nayak, Lakshmi / Chukwueke, Ugonma / Gonzalez Castro, L Nicolas / Dumont, Sydney D / Batchelor, Tracy / Kittelberger, Kara / Tikhonova, Ekaterina / Miheecheva, Natalia / Tabakov, Dmitry / Shin, Nara / Gorbacheva, Alisa / Shumskiy, Artemy / Frenkel, Felix / Aguilar-Cordova, Estuardo / Aguilar, Laura K / Krisky, David / Wechuck, James / Manzanera, Andrea / Matheny, Chris / Tak, Paul P / Barone, Francesca / Kovarsky, Daniel / Tirosh, Itay / Suvà, Mario L / Wucherpfennig, Kai W / Ligon, Keith / Reardon, David A / Chiocca, E Antonio

Nature

2023 Volume 623, Issue 7985, Page(s) 157–166

Abstract: Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM) ...

Abstract	Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)
MeSH term(s)	Humans ; Brain Neoplasms/immunology ; Brain Neoplasms/pathology ; Glioblastoma/immunology ; Glioblastoma/pathology ; Nestin/genetics ; Oncolytic Virotherapy/adverse effects ; Oncolytic Viruses/genetics ; Oncolytic Viruses/immunology ; Oncolytic Viruses/physiology ; Reproducibility of Results ; Survival Analysis ; T-Lymphocytes/cytology ; T-Lymphocytes/immunology ; Treatment Outcome ; Tumor Microenvironment/immunology ; Herpesvirus 1, Human/genetics ; Herpesvirus 1, Human/immunology ; Herpesvirus 1, Human/physiology
Chemical Substances	gamma 34.5 protein, Human herpesvirus 1 ; Nestin
Language	English
Publishing date	2023-10-18
Publishing country	England
Document type	Clinical Trial, Phase I ; Journal Article
ZDB-ID	120714-3
ISSN	1476-4687 ; 0028-0836
ISSN (online)	1476-4687
ISSN	0028-0836
DOI	10.1038/s41586-023-06623-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 26: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 9: Show issues
Zs.MO 244: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors.

Kelly, Paul J / Lin, Nancy U / Claus, Elizabeth B / Quant, Eudocia C / Weiss, Stephanie E / Alexander, Brian M

Cancer

2012 Volume 118, Issue 8, Page(s) 2014–2020

Abstract: Background: Salvage stereotactic radiosurgery (SRS) is often considered in breast cancer patients previously treated for brain metastases. The goal of this study was to analyze clinical outcomes and prognostic factors for survival in the salvage setting. ...

Abstract	Background: Salvage stereotactic radiosurgery (SRS) is often considered in breast cancer patients previously treated for brain metastases. The goal of this study was to analyze clinical outcomes and prognostic factors for survival in the salvage setting. Methods: The authors retrospectively examined 79 consecutive breast cancer patients who received salvage SRS (interval of >3 months after initial therapy), 76 of whom (96%) received prior whole-brain radiation therapy. Overall survival (OS) and central nervous system (CNS) progression-free survival rates were calculated from the date of SRS using the Kaplan-Meier method. Prognostic factors were evaluated using the Cox proportional hazards model. Results: Median age was 50.5 years. Fifty-eight percent of this population was estrogen receptor positive, 62% was HER2 positive, and 10% was triple negative. At the time of SRS, 95% had extracranial metastases, with 81% of extracranial metastases at other visceral sites (lung/pleura/liver). Forty-eight percent had stable extracranial disease. Median interval from initial brain metastases therapy to SRS was 8.4 months. Median CNS progression-free survival after SRS was 5.7 months (interquartile range [IQR], 3.6-11 months), and median OS was 9.8 months (IQR, 3.8-18 months). Eighty-two percent of evaluable patients received further systemic therapy after SRS. HER2 status (adjusted hazard ratio [HR], 2.4; P = .008) and extracranial disease status (adjusted HR, 2.7; P = .004) were significant prognostic factors for survival on multivariate analysis. Conclusions: In patients with good Karnofsky performance status, salvage SRS for breast cancer brain metastases is a reasonable treatment option, given an associated median survival in excess of 9 months. Furthermore, patients with HER2-positive tumors at diagnosis or stable extracranial disease at the time of SRS have an improved clinical course, with median survival of >1 year.
MeSH term(s)	Adult ; Brain Neoplasms/mortality ; Brain Neoplasms/radiotherapy ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Breast Neoplasms/radiotherapy ; Female ; Humans ; Middle Aged ; Prognosis ; Radiosurgery/methods ; Retrospective Studies ; Salvage Therapy ; Treatment Outcome
Language	English
Publishing date	2012-04-15
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.26343
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon, David A / Lassman, Andrew B / Schiff, David / Yunus, Shakeeb A / Gerstner, Elizabeth R / Cloughesy, Timothy F / Lee, Eudocia Quant / Gaffey, Sarah C / Barrs, Jennifer / Bruno, Jennifer / Muzikansky, Alona / Duda, Daniel G / Jain, Rakesh K / Wen, Patrick Y

Cancer

2017 Volume 124, Issue 7, Page(s) 1438–1448

Abstract: Background: Angiopoietins contribute to tumor angiogenesis and may be upregulated as a compensatory factor after vascular endothelial growth factor (VEGF) blockade. The authors performed a phase 2 and biomarker study to evaluate trebananib, an ... ...

Abstract	Background: Angiopoietins contribute to tumor angiogenesis and may be upregulated as a compensatory factor after vascular endothelial growth factor (VEGF) blockade. The authors performed a phase 2 and biomarker study to evaluate trebananib, an angiopoietin 1 and angiopoietin 2 blocking peptibody, with and without bevacizumab in patients with recurrent glioblastoma. Methods: Forty-eight patients who had bevacizumab-naive, recurrent glioblastoma were treated with trebananib (30 mg/kg weekly) as single agent (n = 11) or combined with bevacizumab (n = 37). The primary endpoint was 6-month progression-free survival rate as determined by investigator review. Circulating biomarker levels were assessed before and after study therapy. Results: Trebananib was well tolerated as monotherapy and did not enhance bevacizumab-associated toxicity. Trebananib had no single-agent activity, and all treated patients exhibited progressive disease within 2 months. The 6-month progression-free survival rate for trebananib plus bevacizumab was 24.3% (95% confidence interval [CI], 12.1%-38.8%); whereas the median overall survival was 9.5 months (95% CI, 7.5-4.7 months), and the 12-month overall survival rate was 37.8% (95% CI, 22.6%-53.0%). Baseline and post-treatment changes in circulating vascular VEGF and interleukin-8 levels were correlated with survival among patients who received trebananib plus bevacizumab. Conclusions: Angiopoietin 1 and angiopoietin 2 inhibition with trebananib was ineffective as monotherapy and did not enhance the ability of VEGF blockade with bevacizumab to improve the outcomes of patients with recurrent glioblastoma. Cancer 2018;124:1438-48. © 2017 American Cancer Society.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Angiopoietins/antagonists & inhibitors ; Angiopoietins/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Biomarkers, Tumor/metabolism ; Cohort Studies ; Female ; Follow-Up Studies ; Glioblastoma/drug therapy ; Glioblastoma/metabolism ; Glioblastoma/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Recombinant Fusion Proteins/administration & dosage ; Survival Rate
Chemical Substances	Angiopoietins ; Biomarkers, Tumor ; Recombinant Fusion Proteins ; Bevacizumab (2S9ZZM9Q9V) ; trebananib (X8Y5U6NC7E)
Language	English
Publishing date	2017-12-19
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.31172
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.

Scott, Brian J / Quant, Eudocia C / McNamara, Margaret B / Ryg, Peter A / Batchelor, Tracy T / Wen, Patrick Y

Neuro-oncology

2010 Volume 12, Issue 6, Page(s) 603–607

Abstract: Agents targeting the vascular endothelial growth factor (VEGF) pathway are being used with increasing frequency in patients with recurrent high-grade glioma. The effect of more than one antiangiogenic therapy given in succession has not been established. ...

Abstract	Agents targeting the vascular endothelial growth factor (VEGF) pathway are being used with increasing frequency in patients with recurrent high-grade glioma. The effect of more than one antiangiogenic therapy given in succession has not been established. We reviewed the efficacy of bevacizumab, a VEGF-A monoclonal antibody, in patients who progressed following prior therapy with VEGF receptor tyrosine kinase inhibitors (R-TKi). Seventy-three patients with recurrent high-grade gliomas received VEGF R-TKi (cediranib, sorafenib, pazopanib, or sunitinib) as part of phase I or II clinical trials. Twenty-four of these patients with glioblastoma progressed and received bevacizumab-containing regimens immediately after R-TKi. Those who stopped R-TKi therapy for reasons other than disease progression, or received a treatment that did not include bevacizumab, were excluded from the analysis. The efficacy of bevacizumab-containing regimens in these 24 patients was evaluated. During R-TKi therapy, 6 of 24 patients (25%) had a partial response (PR) to treatment. The 6-month progression-free survival (APF6) was 16.7% and median time-to-progression (TTP) was 14.3 weeks. Grade III/IV toxicities were seen in 13 of 24 patients (54%). Subsequently with bevacizumab salvage therapy, 5 of 24 patients (21%) had a PR, the APF6 was 12.5%, and the median TTP was 8 weeks. Five of 24 patients had grade III/IV toxicities (21%). The median overall survival (OS) from the start of R-TKi therapy was 9.2 months (range: 2.8-34.1+), whereas the median OS after bevacizumab was 5.2 months (range: 1.3-28.9+). Bevacizumab retains modest activity in high-grade glioma patients who progress on R-TKi. However, the APF6 of 12.5% in this cohort of patients indicates that durable tumor control is not achieved for most patients.
MeSH term(s)	Adult ; Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Brain Neoplasms/drug therapy ; Brain Neoplasms/enzymology ; Brain Neoplasms/pathology ; Disease Progression ; Female ; Glioma/drug therapy ; Glioma/enzymology ; Glioma/pathology ; Humans ; Male ; Middle Aged ; Neoplasm Staging/methods ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/metabolism ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Receptors, Vascular Endothelial Growth Factor/metabolism ; Retrospective Studies ; Salvage Therapy/methods ; Young Adult
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Bevacizumab (2S9ZZM9Q9V) ; Receptor Protein-Tyrosine Kinases (EC 2.7.10.1) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1)
Language	English
Publishing date	2010-02-14
Publishing country	England
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2028601-6
ISSN	1523-5866 ; 1522-8517
ISSN (online)	1523-5866
ISSN	1522-8517
DOI	10.1093/neuonc/nop073
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5307: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito